MX367959B - Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi- 2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos. - Google Patents

Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi- 2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos.

Info

Publication number
MX367959B
MX367959B MX2018002236A MX2018002236A MX367959B MX 367959 B MX367959 B MX 367959B MX 2018002236 A MX2018002236 A MX 2018002236A MX 2018002236 A MX2018002236 A MX 2018002236A MX 367959 B MX367959 B MX 367959B
Authority
MX
Mexico
Prior art keywords
naphthyridine
carboxamide
methoxyphenyl
ethoxy
cyano
Prior art date
Application number
MX2018002236A
Other languages
English (en)
Other versions
MX2018002236A (es
Inventor
Platzek Johannes
Gottfried Kathrin
Assmann Jens
Lolli Giulio
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2018002236A publication Critical patent/MX2018002236A/es
Publication of MX367959B publication Critical patent/MX367959B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/23—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/25—Reduction

Abstract

La presente invención se refiere a un procedimiento nuevo para la preparación de (4S)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil -1,4-dihidro-1,6-naftiridina-3-carboxamida de la fórmula (I) y para la recuperación de (4S)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2, 8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida de la fórmula (I) (ver Fórmula) a partir de (4R)-4-(4-ciano-2-metoxifenilo)-5-et oxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida de la fórmula ent-(I) (ver Fórmula).
MX2018002236A 2015-08-21 2016-08-18 Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi- 2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos. MX367959B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15182040 2015-08-21
EP15182042 2015-08-21
PCT/EP2016/069567 WO2017032678A1 (de) 2015-08-21 2016-08-18 Verfahren zur herstellung von (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und wiedergewinnung von (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid mittels elektrochemischer methoden

Publications (2)

Publication Number Publication Date
MX2018002236A MX2018002236A (es) 2018-03-23
MX367959B true MX367959B (es) 2019-09-12

Family

ID=56694167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002236A MX367959B (es) 2015-08-21 2016-08-18 Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi- 2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos.

Country Status (31)

Country Link
US (1) US10392384B2 (es)
EP (1) EP3337801B1 (es)
JP (1) JP6843120B2 (es)
KR (1) KR20180043305A (es)
CN (1) CN108137587B (es)
AU (1) AU2016311135C1 (es)
CA (1) CA2995949A1 (es)
CL (1) CL2018000426A1 (es)
CO (1) CO2018001759A2 (es)
DK (1) DK3337801T3 (es)
ES (1) ES2739907T3 (es)
HK (1) HK1252212A1 (es)
HR (1) HRP20191476T1 (es)
HU (1) HUE044678T2 (es)
IL (1) IL257522B (es)
JO (1) JOP20160185B1 (es)
LT (1) LT3337801T (es)
MX (1) MX367959B (es)
NZ (1) NZ739993A (es)
PE (1) PE20180555A1 (es)
PL (1) PL3337801T3 (es)
PT (1) PT3337801T (es)
RS (1) RS59086B1 (es)
RU (1) RU2715226C2 (es)
SG (1) SG11201801378VA (es)
SI (1) SI3337801T1 (es)
TW (1) TWI725044B (es)
UA (1) UA124418C2 (es)
UY (1) UY36863A (es)
WO (1) WO2017032678A1 (es)
ZA (1) ZA201801867B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560922A1 (de) * 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
WO2020132716A1 (en) * 2018-12-24 2020-07-02 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN110195238B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种三氯甲基吡啶衍生物电化学脱氯制备酰胺的方法
CN110195239B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种多氯甲基吡啶衍生物电化学脱氯制备醛、酸的方法
CN111910206B (zh) * 2019-05-07 2023-03-10 中国科学技术大学 一种合成3-氰基取代的咪唑并[1,5-a]喹啉类化合物的方法
WO2021074072A1 (de) * 2019-10-17 2021-04-22 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester
CN114698375A (zh) * 2019-10-17 2022-07-01 拜耳公司 通过非对映酒石酸酯拆分外消旋体制备2-氰基乙基(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-羧酸酯的方法
AU2020365351A1 (en) * 2019-10-17 2022-05-12 Bayer Aktiengesellschaft Photochemical process for producing (4R,4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide
TW202214624A (zh) 2020-06-16 2022-04-16 德商拜耳廠股份有限公司 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法
CN113214248B (zh) * 2021-04-13 2022-04-26 湖南南新制药股份有限公司 一种1,4-二氢-1,6-萘啶衍生物、药物组合物及其用途
CN113897631B (zh) * 2021-10-24 2023-05-09 昆明学院 电化学合成吡啶-2-酮衍生物的方法
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
CN114605410B (zh) * 2022-04-06 2023-12-29 浙江科聚生物医药有限公司 一种非奈利酮原料药的制备方法
WO2023205164A1 (en) 2022-04-18 2023-10-26 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
CN115583866A (zh) * 2022-08-30 2023-01-10 上海厚博生物科技有限公司 一种用非奈利酮对映体制备非奈利酮的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
JP2009501199A (ja) 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung

Also Published As

Publication number Publication date
AU2016311135C1 (en) 2022-10-13
KR20180043305A (ko) 2018-04-27
EP3337801A1 (de) 2018-06-27
HUE044678T2 (hu) 2019-11-28
DK3337801T3 (da) 2019-08-19
PE20180555A1 (es) 2018-04-02
AU2016311135B2 (en) 2020-09-10
NZ739993A (en) 2022-05-27
SG11201801378VA (en) 2018-03-28
TW201722943A (zh) 2017-07-01
EP3337801B1 (de) 2019-06-12
JP6843120B2 (ja) 2021-03-17
ES2739907T3 (es) 2020-02-04
UY36863A (es) 2017-03-31
ZA201801867B (en) 2019-10-30
CN108137587A (zh) 2018-06-08
CN108137587B (zh) 2020-10-23
BR112018003334A2 (pt) 2018-09-18
UA124418C2 (uk) 2021-09-15
RU2715226C2 (ru) 2020-02-26
IL257522B (en) 2020-04-30
HK1252212A1 (zh) 2019-05-24
JOP20160185B1 (ar) 2021-08-17
SI3337801T1 (sl) 2019-08-30
RU2018109762A (ru) 2019-09-23
MX2018002236A (es) 2018-03-23
PL3337801T3 (pl) 2019-10-31
AU2016311135A1 (en) 2018-03-15
CL2018000426A1 (es) 2018-07-20
US10392384B2 (en) 2019-08-27
IL257522A (en) 2018-04-30
US20180244668A1 (en) 2018-08-30
HRP20191476T1 (hr) 2019-11-15
CO2018001759A2 (es) 2018-02-28
TWI725044B (zh) 2021-04-21
PT3337801T (pt) 2019-08-05
RU2018109762A3 (es) 2019-12-18
WO2017032678A1 (de) 2017-03-02
LT3337801T (lt) 2019-08-12
RS59086B1 (sr) 2019-09-30
JP2018523697A (ja) 2018-08-23
CA2995949A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MX367959B (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi- 2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos.
MX369467B (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenil )-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico.
PH12019501842A1 (en) Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PH12018500457A1 (en) New phenoxymethyl derivatives
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12016501633B1 (en) Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
MX2018002027A (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico.
MX2020005653A (es) Compuestos para la separacion de elementos de tierras raras y metales s, p, d, metodo de separacion y uso de estos.
PH12018550165A1 (en) An improved process for the preparation of butorphanol tartrate
IN2014MU00675A (es)
PH12016501613B1 (en) Pyrazines modulators of gpr6
ZA201801865B (en) Method for the preparation of the metabolites of (4s)- and (4r)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and the use thereof
MX2016009325A (es) Metodo para la preparacion de 1-alquil-3-difluorometil-5-fluor-1h- pirazol-4-carbaldehidos y 1-alquil-3-difluorometil-5-fluor-1h-pira zol-4-carboxilatos.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2014MU00197A (es)
IN2015CH02092A (es)
IN2014MU00069A (es)
IN2014CH01750A (es)
IN2013CH05982A (es)

Legal Events

Date Code Title Description
FG Grant or registration